Prev: Biophosphates - long term use
Next: Optimal vitamin D levels in relation to bone mineral density
From: Juhana Harju on 18 Sep 2006 02:11
In Japan a specific form of vitamin K2, menatetrenone, is used in the
treatment of osteoporosis. There are some studies showing that menatetrenone
is especially effective when used in combination with vitamin D.

The regular treatment dose of menatetrenone is 3 x 15 mg/ day.

Vitamin K treatment is not suitable for people using warfarin (a blood
thinner).

-----------------------------------------------------------------------------------------

(1) Nippon Rinsho. 2006 Sep;64(9):1639-43.
[Active vitamin D and vitamin K as therapeutic agents for
osteoporosis][Article in Japanese]
Katagiri H.
Department of Orthopaedic Surgery, Medicine of Sensory and Motor Organs,
Faculty of Medicine, Tottori University.

Active vitamin D has been most widely used in Japan for the treatment of
osteoporosis. However, clinical evidence for its efficacy as an
anti-osteoporotic drug is scarce in terms of fracture prevention. Recent
reports suggest that active vitamin D may prevent fracture not only through
enhancement of intestinal calcium absorption but also by improving bone
quality and/or strength independently of bone mass and by improving
neuromuscular function to reduce the number of fall. Low serum
concentrations of vitamin K have been reported in patients with
osteoporosis, and serum osteocalcin appears to be undercarboxylated in these
individuals, a process dependent on vitamin K. Undercarboxylated osteocalcin
is also a significant risk for hip fracture. Clinical studies in Japan
suggest that menatetrenone (vitamin K2) reduces skeletal losses and, in a
small randomized clinical trial, it reduced the rate of vertebral fractures.
Menatetrenone is currently used in Japan, the Republic of Korea and
Thailand. PMID: 16972672


(2) J Orthop Sci. 2000;5(6):546-51.
Effect of combined administration of vitamin D3 and vitamin K2 on bone
mineral density of the lumbar spine in postmenopausal women with
osteoporosis.
Iwamoto J, Takeda T, Ichimura S.
Department of Sports Clinic, Keio University School of Medicine, 35
Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

The effect of the combined administration of vitamin D3 and vitamin K2 on
bone mineral density (BMD) of the lumbar spine was examined in
postmenopausal women with osteoporosis. Ninety-two osteoporotic women who
were more than 5 years after menopause, aged 55-81 years, were randomly
divided into four administration groups: vitamin D3 (1alpha hydroxyvitamin
D3, 0.75 microg/day) (D group; n = 29), vitamin K2 (menatetrenone, 45
mg/day) (K group; n = 22), vitamin D3 plus vitamin K2 (DK group, n = 21),
and calcium (calcium lactate, 2 g/day) (C group; n = 20). BMD of the lumbar
spine (L2-L4) was measured by dual energy X-ray absorptiometry at 0, 1, and
2 years after the treatment started. There were no significant differences
in age, body mass index, years since menopause, and initial BMD among the
four groups. One-way analysis of variance (ANOVA) with repeated measurements
showed a significant decrease in BMD in the C group (P < 0.001). Two-way
ANOVA with repeated measurements showed a significant increase in BMD in the
D and K groups compared with that in the C group (P < 0.05 and P < 0.001,
respectively), and a significant increase in BMD in the DK group compared
with that in the C, D, and K groups (P < 0.0001, P < 0.05 and P < 0.01,
respectively). These findings indicate that combined administration of
vitamin D3 and vitamin K2, compared with calcium administration, appears to
be useful in increasing the BMD of the lumbar spine in postmenopausal women
with osteoporosis. PMID: 11180916

--
Juhana


From: Pam on 19 Sep 2006 16:30
Hi Juhana: Have you had any success with K2? I wasn't sure if you were just
posting the medical info or not. I've haven't tried this for osteo... because
it is kind of pricey. I've talked to people with osteo... that are eating
natto instead to get their K2, and they feel that their BMD's have gone up
because of this. Of course it would be hard to differentiate what helped them
if they are also taking other meds like bisphosphonates, or PTH.

Let me know, if you've tried K2 with any noticeable results.

TIA

Pam
"Juhana Harju" <spamshantigiriorama.removespam(a)gmail.com> wrote in message
news:4n6rl5F92487U1(a)individual.net...
> In Japan a specific form of vitamin K2, menatetrenone, is used in the
> treatment of osteoporosis. There are some studies showing that menatetrenone
> is especially effective when used in combination with vitamin D.
>
> The regular treatment dose of menatetrenone is 3 x 15 mg/ day.
>
> Vitamin K treatment is not suitable for people using warfarin (a blood
> thinner).
>
> -----------------------------------------------------------------------------------------
>
> (1) Nippon Rinsho. 2006 Sep;64(9):1639-43.
> [Active vitamin D and vitamin K as therapeutic agents for
> osteoporosis][Article in Japanese]
> Katagiri H.
> Department of Orthopaedic Surgery, Medicine of Sensory and Motor Organs,
> Faculty of Medicine, Tottori University.
>
> Active vitamin D has been most widely used in Japan for the treatment of
> osteoporosis. However, clinical evidence for its efficacy as an
> anti-osteoporotic drug is scarce in terms of fracture prevention. Recent
> reports suggest that active vitamin D may prevent fracture not only through
> enhancement of intestinal calcium absorption but also by improving bone
> quality and/or strength independently of bone mass and by improving
> neuromuscular function to reduce the number of fall. Low serum
> concentrations of vitamin K have been reported in patients with
> osteoporosis, and serum osteocalcin appears to be undercarboxylated in these
> individuals, a process dependent on vitamin K. Undercarboxylated osteocalcin
> is also a significant risk for hip fracture. Clinical studies in Japan
> suggest that menatetrenone (vitamin K2) reduces skeletal losses and, in a
> small randomized clinical trial, it reduced the rate of vertebral fractures.
> Menatetrenone is currently used in Japan, the Republic of Korea and
> Thailand. PMID: 16972672
>
>
> (2) J Orthop Sci. 2000;5(6):546-51.
> Effect of combined administration of vitamin D3 and vitamin K2 on bone
> mineral density of the lumbar spine in postmenopausal women with
> osteoporosis.
> Iwamoto J, Takeda T, Ichimura S.
> Department of Sports Clinic, Keio University School of Medicine, 35
> Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
>
> The effect of the combined administration of vitamin D3 and vitamin K2 on
> bone mineral density (BMD) of the lumbar spine was examined in
> postmenopausal women with osteoporosis. Ninety-two osteoporotic women who
> were more than 5 years after menopause, aged 55-81 years, were randomly
> divided into four administration groups: vitamin D3 (1alpha hydroxyvitamin
> D3, 0.75 microg/day) (D group; n = 29), vitamin K2 (menatetrenone, 45
> mg/day) (K group; n = 22), vitamin D3 plus vitamin K2 (DK group, n = 21),
> and calcium (calcium lactate, 2 g/day) (C group; n = 20). BMD of the lumbar
> spine (L2-L4) was measured by dual energy X-ray absorptiometry at 0, 1, and
> 2 years after the treatment started. There were no significant differences
> in age, body mass index, years since menopause, and initial BMD among the
> four groups. One-way analysis of variance (ANOVA) with repeated measurements
> showed a significant decrease in BMD in the C group (P < 0.001). Two-way
> ANOVA with repeated measurements showed a significant increase in BMD in the
> D and K groups compared with that in the C group (P < 0.05 and P < 0.001,
> respectively), and a significant increase in BMD in the DK group compared
> with that in the C, D, and K groups (P < 0.0001, P < 0.05 and P < 0.01,
> respectively). These findings indicate that combined administration of
> vitamin D3 and vitamin K2, compared with calcium administration, appears to
> be useful in increasing the BMD of the lumbar spine in postmenopausal women
> with osteoporosis. PMID: 11180916
>
> --
> Juhana
>
>


From: Pam on 19 Sep 2006 16:35
Juhana: If you want to discuss this topic any further, you can go to
http://www.healthboards.com/ to do so. Sign up is free, and there are quite a
bit of discussions on osteo, and just about any other health topic you can think
of. If you haven't been to that forum, just make sure you read their rules for
posting, as all the groups are moderated, and rules are "strictly" enforced.

Pam
"Pam" <phflores~nospam~@verizon.net> wrote in message
news:prYPg.7622$832.6066(a)trnddc04...
> Hi Juhana: Have you had any success with K2? I wasn't sure if you were just
> posting the medical info or not. I've haven't tried this for osteo... because
> it is kind of pricey. I've talked to people with osteo... that are eating
> natto instead to get their K2, and they feel that their BMD's have gone up
> because of this. Of course it would be hard to differentiate what helped them
> if they are also taking other meds like bisphosphonates, or PTH.
>
> Let me know, if you've tried K2 with any noticeable results.
>
> TIA
>
> Pam
> "Juhana Harju" <spamshantigiriorama.removespam(a)gmail.com> wrote in message
> news:4n6rl5F92487U1(a)individual.net...
>> In Japan a specific form of vitamin K2, menatetrenone, is used in the
>> treatment of osteoporosis. There are some studies showing that menatetrenone
>> is especially effective when used in combination with vitamin D.
>>
>> The regular treatment dose of menatetrenone is 3 x 15 mg/ day.
>>
>> Vitamin K treatment is not suitable for people using warfarin (a blood
>> thinner).
>>
>> -----------------------------------------------------------------------------------------
>>
>> (1) Nippon Rinsho. 2006 Sep;64(9):1639-43.
>> [Active vitamin D and vitamin K as therapeutic agents for
>> osteoporosis][Article in Japanese]
>> Katagiri H.
>> Department of Orthopaedic Surgery, Medicine of Sensory and Motor Organs,
>> Faculty of Medicine, Tottori University.
>>
>> Active vitamin D has been most widely used in Japan for the treatment of
>> osteoporosis. However, clinical evidence for its efficacy as an
>> anti-osteoporotic drug is scarce in terms of fracture prevention. Recent
>> reports suggest that active vitamin D may prevent fracture not only through
>> enhancement of intestinal calcium absorption but also by improving bone
>> quality and/or strength independently of bone mass and by improving
>> neuromuscular function to reduce the number of fall. Low serum
>> concentrations of vitamin K have been reported in patients with
>> osteoporosis, and serum osteocalcin appears to be undercarboxylated in these
>> individuals, a process dependent on vitamin K. Undercarboxylated osteocalcin
>> is also a significant risk for hip fracture. Clinical studies in Japan
>> suggest that menatetrenone (vitamin K2) reduces skeletal losses and, in a
>> small randomized clinical trial, it reduced the rate of vertebral fractures.
>> Menatetrenone is currently used in Japan, the Republic of Korea and
>> Thailand. PMID: 16972672
>>
>>
>> (2) J Orthop Sci. 2000;5(6):546-51.
>> Effect of combined administration of vitamin D3 and vitamin K2 on bone
>> mineral density of the lumbar spine in postmenopausal women with
>> osteoporosis.
>> Iwamoto J, Takeda T, Ichimura S.
>> Department of Sports Clinic, Keio University School of Medicine, 35
>> Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
>>
>> The effect of the combined administration of vitamin D3 and vitamin K2 on
>> bone mineral density (BMD) of the lumbar spine was examined in
>> postmenopausal women with osteoporosis. Ninety-two osteoporotic women who
>> were more than 5 years after menopause, aged 55-81 years, were randomly
>> divided into four administration groups: vitamin D3 (1alpha hydroxyvitamin
>> D3, 0.75 microg/day) (D group; n = 29), vitamin K2 (menatetrenone, 45
>> mg/day) (K group; n = 22), vitamin D3 plus vitamin K2 (DK group, n = 21),
>> and calcium (calcium lactate, 2 g/day) (C group; n = 20). BMD of the lumbar
>> spine (L2-L4) was measured by dual energy X-ray absorptiometry at 0, 1, and
>> 2 years after the treatment started. There were no significant differences
>> in age, body mass index, years since menopause, and initial BMD among the
>> four groups. One-way analysis of variance (ANOVA) with repeated measurements
>> showed a significant decrease in BMD in the C group (P < 0.001). Two-way
>> ANOVA with repeated measurements showed a significant increase in BMD in the
>> D and K groups compared with that in the C group (P < 0.05 and P < 0.001,
>> respectively), and a significant increase in BMD in the DK group compared
>> with that in the C, D, and K groups (P < 0.0001, P < 0.05 and P < 0.01,
>> respectively). These findings indicate that combined administration of
>> vitamin D3 and vitamin K2, compared with calcium administration, appears to
>> be useful in increasing the BMD of the lumbar spine in postmenopausal women
>> with osteoporosis. PMID: 11180916
>>
>> --
>> Juhana
>>
>>
>
>


From: Juhana Harju on 19 Sep 2006 17:08
Pam wrote:
: Hi Juhana: Have you had any success with K2? I wasn't sure if you
: were just posting the medical info or not. I've haven't tried this
: for osteo... because it is kind of pricey. I've talked to people
: with osteo... that are eating natto instead to get their K2, and they
: feel that their BMD's have gone up because of this. Of course it
: would be hard to differentiate what helped them if they are also
: taking other meds like bisphosphonates, or PTH.
:
: Let me know, if you've tried K2 with any noticeable results.

Hi,

I have not tried it. I was just impressed by some studies I saw. I decided
to post to this group to inform people as I noticed that there has not been
any postings about menatetrenone to this group. It is rather expensive, but
I think that it is perhaps worth of money. If I would try menatetrenone, I
would combine it with a high dose of vitamin D because of the beneficial
synergistic effects.

Natto, made from fermented soybean, should work also if it is incorporated
to the daily diet, but it is not available everywhere. Some people might
also find it not so palatable.

--
Juhana



: "Juhana Harju" <spamshantigiriorama.removespam(a)gmail.com> wrote in
: message news:4n6rl5F92487U1(a)individual.net...
:: In Japan a specific form of vitamin K2, menatetrenone, is used in the
:: treatment of osteoporosis. There are some studies showing that
:: menatetrenone is especially effective when used in combination with
:: vitamin D.
::
:: The regular treatment dose of menatetrenone is 3 x 15 mg/ day.
::
:: Vitamin K treatment is not suitable for people using warfarin (a
:: blood thinner).
::
:: -----------------------------------------------------------------------------------------
::
:: (1) Nippon Rinsho. 2006 Sep;64(9):1639-43.
:: [Active vitamin D and vitamin K as therapeutic agents for
:: osteoporosis][Article in Japanese]
:: Katagiri H.
:: Department of Orthopaedic Surgery, Medicine of Sensory and Motor
:: Organs, Faculty of Medicine, Tottori University.
::
:: Active vitamin D has been most widely used in Japan for the
:: treatment of osteoporosis. However, clinical evidence for its
:: efficacy as an anti-osteoporotic drug is scarce in terms of fracture
:: prevention. Recent reports suggest that active vitamin D may prevent
:: fracture not only through enhancement of intestinal calcium
:: absorption but also by improving bone quality and/or strength
:: independently of bone mass and by improving neuromuscular function
:: to reduce the number of fall. Low serum concentrations of vitamin K
:: have been reported in patients with osteoporosis, and serum
:: osteocalcin appears to be undercarboxylated in these individuals, a
:: process dependent on vitamin K. Undercarboxylated osteocalcin is
:: also a significant risk for hip fracture. Clinical studies in Japan
:: suggest that menatetrenone (vitamin K2) reduces skeletal losses and,
:: in a small randomized clinical trial, it reduced the rate of
:: vertebral fractures. Menatetrenone is currently used in Japan, the
:: Republic of Korea and Thailand. PMID: 16972672
::
::
:: (2) J Orthop Sci. 2000;5(6):546-51.
:: Effect of combined administration of vitamin D3 and vitamin K2 on
:: bone mineral density of the lumbar spine in postmenopausal women with
:: osteoporosis.
:: Iwamoto J, Takeda T, Ichimura S.
:: Department of Sports Clinic, Keio University School of Medicine, 35
:: Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
::
:: The effect of the combined administration of vitamin D3 and vitamin
:: K2 on bone mineral density (BMD) of the lumbar spine was examined in
:: postmenopausal women with osteoporosis. Ninety-two osteoporotic
:: women who were more than 5 years after menopause, aged 55-81 years,
:: were randomly divided into four administration groups: vitamin D3
:: (1alpha hydroxyvitamin D3, 0.75 microg/day) (D group; n = 29),
:: vitamin K2 (menatetrenone, 45 mg/day) (K group; n = 22), vitamin D3
:: plus vitamin K2 (DK group, n = 21), and calcium (calcium lactate, 2
:: g/day) (C group; n = 20). BMD of the lumbar spine (L2-L4) was
:: measured by dual energy X-ray absorptiometry at 0, 1, and 2 years
:: after the treatment started. There were no significant differences
:: in age, body mass index, years since menopause, and initial BMD
:: among the four groups. One-way analysis of variance (ANOVA) with
:: repeated measurements showed a significant decrease in BMD in the C
:: group (P < 0.001). Two-way ANOVA with repeated measurements showed a
:: significant increase in BMD in the D and K groups compared with that
:: in the C group (P < 0.05 and P < 0.001, respectively), and a
:: significant increase in BMD in the DK group compared with that in
:: the C, D, and K groups (P < 0.0001, P < 0.05 and P < 0.01,
:: respectively). These findings indicate that combined administration
:: of vitamin D3 and vitamin K2, compared with calcium administration,
:: appears to be useful in increasing the BMD of the lumbar spine in
:: postmenopausal women with osteoporosis. PMID: 11180916


From: Juhana Harju on 19 Sep 2006 17:20
Pam wrote:
: Juhana: If you want to discuss this topic any further, you can go to
: http://www.healthboards.com/ to do so. Sign up is free, and there
: are quite a bit of discussions on osteo, and just about any other
: health topic you can think of. If you haven't been to that forum,
: just make sure you read their rules for posting, as all the groups
: are moderated, and rules are "strictly" enforced.
:
: Pam

Thanks.

--
Juhana

: "Pam" <phflores~nospam~@verizon.net> wrote in message
: news:prYPg.7622$832.6066(a)trnddc04...
:: Hi Juhana: Have you had any success with K2? I wasn't sure if you
:: were just posting the medical info or not. I've haven't tried this
:: for osteo... because it is kind of pricey. I've talked to people
:: with osteo... that are eating natto instead to get their K2, and
:: they feel that their BMD's have gone up because of this. Of course
:: it would be hard to differentiate what helped them if they are also
:: taking other meds like bisphosphonates, or PTH.
::
:: Let me know, if you've tried K2 with any noticeable results.
::
:: TIA
::
:: Pam
:: "Juhana Harju" <spamshantigiriorama.removespam(a)gmail.com> wrote in
:: message news:4n6rl5F92487U1(a)individual.net...
::: In Japan a specific form of vitamin K2, menatetrenone, is used in
::: the treatment of osteoporosis. There are some studies showing that
::: menatetrenone is especially effective when used in combination with
::: vitamin D.
:::
::: The regular treatment dose of menatetrenone is 3 x 15 mg/ day.
:::
::: Vitamin K treatment is not suitable for people using warfarin (a
::: blood thinner).
:::
::: -----------------------------------------------------------------------------------------
:::
::: (1) Nippon Rinsho. 2006 Sep;64(9):1639-43.
::: [Active vitamin D and vitamin K as therapeutic agents for
::: osteoporosis][Article in Japanese]
::: Katagiri H.
::: Department of Orthopaedic Surgery, Medicine of Sensory and Motor
::: Organs, Faculty of Medicine, Tottori University.
:::
::: Active vitamin D has been most widely used in Japan for the
::: treatment of osteoporosis. However, clinical evidence for its
::: efficacy as an anti-osteoporotic drug is scarce in terms of
::: fracture prevention. Recent reports suggest that active vitamin D
::: may prevent fracture not only through enhancement of intestinal
::: calcium absorption but also by improving bone quality and/or
::: strength independently of bone mass and by improving neuromuscular
::: function to reduce the number of fall. Low serum concentrations of
::: vitamin K have been reported in patients with osteoporosis, and
::: serum osteocalcin appears to be undercarboxylated in these
::: individuals, a process dependent on vitamin K. Undercarboxylated
::: osteocalcin is also a significant risk for hip fracture. Clinical
::: studies in Japan suggest that menatetrenone (vitamin K2) reduces
::: skeletal losses and, in a small randomized clinical trial, it
::: reduced the rate of vertebral fractures. Menatetrenone is currently
::: used in Japan, the Republic of Korea and Thailand. PMID: 16972672
:::
:::
::: (2) J Orthop Sci. 2000;5(6):546-51.
::: Effect of combined administration of vitamin D3 and vitamin K2 on
::: bone mineral density of the lumbar spine in postmenopausal women
::: with osteoporosis.
::: Iwamoto J, Takeda T, Ichimura S.
::: Department of Sports Clinic, Keio University School of Medicine, 35
::: Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
:::
::: The effect of the combined administration of vitamin D3 and vitamin
::: K2 on bone mineral density (BMD) of the lumbar spine was examined in
::: postmenopausal women with osteoporosis. Ninety-two osteoporotic
::: women who were more than 5 years after menopause, aged 55-81 years,
::: were randomly divided into four administration groups: vitamin D3
::: (1alpha hydroxyvitamin D3, 0.75 microg/day) (D group; n = 29),
::: vitamin K2 (menatetrenone, 45 mg/day) (K group; n = 22), vitamin D3
::: plus vitamin K2 (DK group, n = 21), and calcium (calcium lactate, 2
::: g/day) (C group; n = 20). BMD of the lumbar spine (L2-L4) was
::: measured by dual energy X-ray absorptiometry at 0, 1, and 2 years
::: after the treatment started. There were no significant differences
::: in age, body mass index, years since menopause, and initial BMD
::: among the four groups. One-way analysis of variance (ANOVA) with
::: repeated measurements showed a significant decrease in BMD in the C
::: group (P < 0.001). Two-way ANOVA with repeated measurements showed
::: a significant increase in BMD in the D and K groups compared with
::: that in the C group (P < 0.05 and P < 0.001, respectively), and a
::: significant increase in BMD in the DK group compared with that in
::: the C, D, and K groups (P < 0.0001, P < 0.05 and P < 0.01,
::: respectively). These findings indicate that combined administration
::: of vitamin D3 and vitamin K2, compared with calcium administration,
::: appears to be useful in increasing the BMD of the lumbar spine in
::: postmenopausal women with osteoporosis. PMID: 11180916


 |  Next  |  Last
Pages: 1 2
Prev: Biophosphates - long term use
Next: Optimal vitamin D levels in relation to bone mineral density